CLORAZEPATE DIPOTASSIUM SALT

CAS No.
57109-90-7
Chemical Name:
CLORAZEPATE DIPOTASSIUM SALT
Synonyms
Azene;cm4306;cb4306;4306cb;ah3232;mendon;ab35616;latekoh;tr19119;belseren
CBNumber:
CB3737547
Molecular Formula:
C16H13ClK2N2O4
Molecular Weight:
410.94
MDL Number:
MFCD00063405
MOL File:
57109-90-7.mol
Last updated:2023-05-15 10:44:01

CLORAZEPATE DIPOTASSIUM SALT Properties

Melting point 228-235°C
Flash point 11 °C
storage temp. 2-8°C
solubility Freely soluble to very soluble in water, very slightly soluble in alcohol, practically insoluble in methylene chloride. Solutions in water and in alcohol are unstable and are to be used immediately.
form Solid
color White to Pale Yellow
FDA UNII 63FN7G03XY
Proposition 65 List Clorazepate Dipotassium
EPA Substance Registry System Clorazepate dipotassium (57109-90-7)

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictogramsGHS hazard pictograms
GHS07,GHS08
Signal word  Warning
Hazard statements  H302-H361
Precautionary statements  P280-P301+P312+P330
Hazard Codes  Xn,T,F
Risk Statements  22-63-39/23/24/25-23/24/25-11
Safety Statements  22-36/37/39-45-36/37-16-7
RIDADR  3249
WGK Germany  3
RTECS  DE8750000
HazardClass  6.1(b)
PackingGroup  III
HS Code  2933910000
Toxicity LD50 in mice (mg/kg): 700 orally; 290 i.p.; LD50 orally in rats: >1000 mg/kg (Brunaud)

CLORAZEPATE DIPOTASSIUM SALT Chemical Properties,Uses,Production

Chemical Properties

Pale Yellow Solid

Originator

Tranxene,Clin-Comar-Byla,France,1968

Uses

Anxiolytic. Controlled substance (depressant).

Definition

ChEBI: The compound of monopotassium clorazepate with potassium hydroxide. It is used for the management of anxiety disorders, for the short-term relief of anxiety, as adjunctive therapy in the management of epilepsy, and for the symptomatic relief of acute alcoh l withdrawal.

Manufacturing Process

(A) Preparation of (2-Amino-5-Chlorophenyl)Phenylmethaneimine (4356 CB): A solution of 228.7 g (1.5 mold of 2-amino-5-chlorobenzonitrilein 1,800 ml of dry ether is added slowly in the course of about 3.5 hours to a solution of phenyl magnesium bromide prepared from 109 g (4.5 g-atoms) of magnesium turnings and 848 g (5.4 mols) of bromobenzene in 3,600 ml of anhydrous ether, and the mixture then heated under reflux for 15 hours. The complex is decomposed by stirring the reaction mixture into a solution prepared from 500 g of ammonium chloride in 2,000 mi of water to which 3 kg of crushed ice have been added. After extraction and washing, the ether is evaporated in vacuo at 40°C. The oily residue is taken up in 500 ml of petroleum ether and left to crystallize by cooling at -20°C. The yellowish crystals formed are dried (309 g); MPk (Kofler block): 74°C; yield: 92%. (B) Preparation of 7-Chloro-3-Methoxycarbonyl-5-Phenyl-2-Oxo-2,3-Dihydro- 1H-Benzo[f]-1,4-Diazepine (4347 CB): A solution of 9.2 g (0.04 mol) of compound 4356 CB in 20 ml of methanol is added dropwise, in the course of one hour and 30 minutes, to a boiling solution of 9.2 g (0.05 mol) of the hydrochloride of methyl aminomalonate in 30 ml of methanol. When this is completed, heating under reflux is continued for 30 minutes and the product then concentrated to dryness under reduced pressure. The residue is taken up in water and ether, the ethereal layer separated, the product washed with water and dried over sodium sulfate. The solvent is evaporated under reduced pressure. The residue, which consists of the methyl ester, could not be obtained in the crystalline state. It is dissolved in 25 ml of acetic acid, heated under reflux for 15 minutes, the product evaporated to dryness and the residual oil taken up in ether. A colorless solid separates which is filtered by suction and recrystallized from methanol. Colorless crystals are obtained (4.7 9); MPk (Kofler block): 226°C. A second crop (1.5 g) is obtained on concentration of the mother liquor; MPk (Kofler block): 222°C; total quantity 6.2 g, corresponding to a yield of 47%.
(C) Preparation of Dipotassium Salt of [2-Phenyl-2-(2-Amino-5-Chlorophenyl)- 1-Azavinyl] Malonic Acid (4306 CB): 50 g of caustic potash are dissolved in 1,350 ml of 96% ethyl alcohol, and 82 g (0.25 mol) of compound 4347 CB are then added all at once at a temperature of about 70°C. The solid dissolves rapidly to form a yellow solution which then loses color while simultaneously an abundant colorless precipitate appears.
After cooling, the solid is filtered by suction and washed with alcohol at 96°C. The product is dried at ordinary temperature in a high vacuum. A colorless solid is obtained (quantitative yield), which is completely soluble in water. The aqueous solution is strongly alkaline in reaction; when acidified with acetic acid and heated on a water bath, it yields a precipitate of 7-chloro-5-phenyl- 2-oxo-2,3-dihydro-1H-benzo[f]-1,4-diazepine.

brand name

Tranxene (Ovation).

Therapeutic Function

Tranquilizer

General Description

Clorazepate dipotassium,7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid dipotassium salt monohydrate(Tranxene), can be considered a prodrug. Inactive itself, itundergoes rapid decarboxylation by the acidity of thestomach to nordazepam (a major active metabolite of diazepam),which has a long half-life and undergoes hepaticconversion to active oxazepam. Despite the polar characterof the drug as administered, because it is quickly convertedin the GI tract to an active nonpolar compound, it has aquick onset, overall long half-life, and shares similar clinicaland pharmacokinetic properties to chlordiazepoxideand diazepam.

CLORAZEPATE DIPOTASSIUM SALT Preparation Products And Raw materials

Raw materials

Preparation Products

Chlorazepate dipotassic Potassium hydroxide (K(OH)), compd. with 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid monopotassium salt (1:1) (9CI) Potassium hydroxide, compd. with 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid monopotassium salt (1:1) chlorazepate chlorazepatedipotassium clorazepatedipotassium cm4306 Clorazepate dipotassium salt solution Clorazepate Dipotassium CIV (125 mg) belseren bipotassiumchlorazepate cb4306 chlorazepam 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid Apo-Clorazepate Azene Clorazepate potassium Gen-xene Novo-Clopate Nu-Clopate Tranzene CLORAZEPATE DIPOTASSIUM METHANOL*SOLUTIO N CLORAZEPATE DIPOTASSIUM--DEA SCHEDULE I& 1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (K(OH)) (1:1) [2-Phenyl-2-(2-amino-5-chlorophenyl)-1-azavinyl]malonic acid 1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1) tranxene tranxilen tranxilene tranxilium Clorazepate dipotassium solution 7-CHLORO-2,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-1H-1,4-BENZODIAZEPINE-3-CARBOXYLIC ACID DIPOTASSIUM SALT Clorazepic acid dipotassium salt Clorazepate dipotassium salt,7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid Clorazepic Acid DipotasiuM Salt CLORAZEPATE CLORAZEPATE DIPOTASSIUM SALT 4306cb ab35616 abbott-35616 ah3232 dipotassiumchlorazepate dipotassiumclorazepate latekoh mendon monopotassiumsalt,compd.withpotassiumhydroxide nevracten potassium7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepine-3-carboxy tencilan tr19119 transene transilium QCHSEDTUUKDTIG-UHFFFAOYSA-L Potassium (3RS)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H- 1,4-benzodiazepine-3-carboxylate compound with potassium hydroxide (1:1) Dipotsium Clorazepate Dipotassium Clorazepate API 57109-90-7 C16H11ClN2O4K2